← Back to Search

Diagnostic (ferumoxytol, MRI) for Brain Tumor

Phase 2
Waitlist Available
Led By Edward A Neuwelt
Research Sponsored by OHSU Knight Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial uses ferumoxytol, an experimental MRI contrast agent, to study brain tumors in children. The hope is that this agent will give doctors more information about the tumors, including blood supply and extent.

Eligible Conditions
  • Brain Tumor

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Blood Volume
Brain
Delineation of tumor from larger blood vessels
+1 more
Secondary study objectives
Ferumoxytol enhancement
Histology and genetic markers
Progression free survival
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (ferumoxytol, MRI)Experimental Treatment2 Interventions
Patients undergo MRI with GBCA per standard of care over 45-60 minutes and then receive ferumoxytol IV followed by MRI over 10 minutes on day 1. Patients may optionally undergo MRI over 30 minutes without any contrast agent on day 2. Each study visit consisting of 2 days may repeat no more frequently than 4 weeks for up to 5 study visits at different stages of the disease as determined by the investigator.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Magnetic Resonance Imaging
2017
Completed Phase 3
~1160
Ferumoxytol
2011
Completed Phase 4
~4380

Find a Location

Who is running the clinical trial?

AMAG Pharmaceuticals, Inc.Industry Sponsor
43 Previous Clinical Trials
11,314 Total Patients Enrolled
OHSU Knight Cancer InstituteLead Sponsor
234 Previous Clinical Trials
2,088,627 Total Patients Enrolled
Oregon Health and Science UniversityOTHER
994 Previous Clinical Trials
7,386,948 Total Patients Enrolled
~0 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top